Nurix Therapeutics/$NRIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Ticker
$NRIX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
286
ISIN
US67080M1036
Website
NRIX Metrics
BasicAdvanced
$1B
-
-$2.81
2.24
-
Price and volume
Market cap
$1B
Beta
2.24
52-week high
$27.37
52-week low
$8.18
Average daily volume
826K
Financial strength
Current ratio
6.264
Quick ratio
6.132
Long term debt to equity
4.155
Total debt to equity
5.536
Profitability
EBITDA (TTM)
-222.349
Gross margin (TTM)
-327.69%
Net profit margin (TTM)
-369.40%
Operating margin (TTM)
-408.87%
Effective tax rate (TTM)
-0.09%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-31.08%
Return on equity (TTM)
-64.16%
Valuation
Price to revenue (TTM)
17.354
Price to book
2.09
Price to tangible book (TTM)
2.09
Price to free cash flow (TTM)
-4.857
Free cash flow yield (TTM)
-20.59%
Free cash flow per share (TTM)
-271.38%
Growth
Revenue change (TTM)
-30.25%
Earnings per share change (TTM)
5.75%
3-year revenue growth (CAGR)
17.97%
3-year earnings per share growth (CAGR)
-2.77%
What the Analysts think about NRIX
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
Bulls say / Bears say
Nurix Therapeutics has established strategic partnerships with major pharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, which validate its technology platform and offer potential for milestone payments and royalties. (Investing.com)
The company's lead candidate, NX-5948, is progressing towards pivotal trials for chronic lymphocytic leukemia (CLL) in 2025, potentially leading to accelerated approval in certain patient populations. (Investing.com)
Analysts have set an average 12-month price target of $30.7 for Nurix Therapeutics, indicating significant upside potential from its current trading price. (Nasdaq)
Nurix Therapeutics reported a negative EBITDA of $186.4 million in the last twelve months, reflecting ongoing financial challenges typical of clinical-stage biopharmaceutical companies. (Investing.com)
The biotechnology sector is highly competitive, with other companies developing BTK degraders and inhibitors, such as BeiGene's BGB-16673, which has shown similar efficacy in early trials, potentially challenging Nurix's market position. (Investing.com)
Nurix's revenue is anticipated to climb by 16% per year during the coming three years, which is significantly lower than the industry prediction of 140% growth each year, potentially impacting its competitive standing. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
NRIX Financial Performance
Revenues and expenses
NRIX Earnings Performance
Company profitability
NRIX News
AllArticlesVideos
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewsWire·1 day ago
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
GlobeNewsWire·3 days ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $1B as of July 10, 2025.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of July 10, 2025.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.